Adult AML Protocols Improve Survival in Young Patients
A 2026 study shows young adults with AML see significantly better outcomes when treated with adult, rather than pediatric, protocols.
Updated on Oct. 21, 2026 in Cancer
A retrospective study published in 2026 found that adolescents and young adults diagnosed with acute myeloid leukemia (AML) achieve higher survival rates using adult-based treatment regimens. Data from the 81-patient cohort suggests that adult protocols offer a substantial survival advantage for this specific age group.
Why it matters
The findings challenge traditional approaches to treating young adults with AML, suggesting that age-appropriate protocol selection is critical for patient survival. Understanding these differences helps clinicians optimize care pathways for patients between 14 and 29 years old.
The adult protocol achieved a 77.9% five-year survival rate compared to 56.7% for the pediatric protocol among 81 patients aged 14 to 29. Transplants also showed higher success, with 78.6% survival for the adult cohort versus 43.6% for the pediatric group.
The players
Memorial Sloan Kettering Cancer Center
This is a world-renowned cancer treatment and research institution based in New York City that serves as a hub for oncology clinical trials.
The details
Researchers at Memorial Sloan Kettering Cancer Center found that adult induction involving cytarabine and daunorubicin outperformed the pediatric regimen of cytarabine, daunorubicin, and etoposide. Patients on the adult protocol also demonstrated higher rates of negative minimal residual disease.
Timeline
Patients in the study cohort were diagnosed between 2010 and 2025.
The findings were published in the journal Blood Advances in 2026.
The Big Picture
This study extends the clinical research output generated by the Memorial Sloan Kettering Cancer Center. It highlights a shift toward prioritizing biological markers and patient age over legacy pediatric treatment standards in adolescent oncology.
Patients and families may use these findings to discuss protocol options with their oncology care teams. This evidence provides a basis for questioning whether adult-based regimens could offer better long-term outcomes for adolescent and young adult diagnoses.
The takeaway
Clinicians should consider the significant survival disparity between pediatric and adult treatment protocols when designing care plans for young adults. Tailoring therapy based on this evidence could potentially improve long-term outcomes for patients within this specific age bracket.
Further reading
For more information on current treatment standards, visit the Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
